Inhibition of Notch1 increases paclitaxel sensitivity to human breast cancer

Chinese Medical Journal

Volumn 127, Issue 3, 2014, Pages 442-447

  Zhao, Li ^a,b   Ma, Yong Jie ^a,b   Gu, Feng ^a,b   Fu, Li ^a,b  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b KEY LABORATORY OF CANCER PREVENTION AND THERAPY   (China)

Author keywords

Breast cancer; Notch1; Paclitaxel sensitivity

Indexed keywords

NOTCH1 RECEPTOR; PACLITAXEL; SMALL INTERFERING RNA; ANTINEOPLASTIC AGENT; DIPEPTIDE; N-(N-(3,5-DIFLUOROPHENACETYL)ALANYL)PHENYLGLYCINE TERT-BUTYL ESTER; NOTCH1 PROTEIN, HUMAN;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG SENSITIVITY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MTT ASSAY; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; BREAST TUMOR; CELL SURVIVAL; DRUG EFFECTS; METABOLISM; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; DIPEPTIDES; HUMANS; IMMUNOHISTOCHEMISTRY; PACLITAXEL; RECEPTOR, NOTCH1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84893110225     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20120230     Document Type: Article

References (30)

1. Lacey JV, Jr, Devesa SS, Brinton LA. Recent trends in breast cancer incidence and mortality. Environ Mol Mutagen 2002; 39: 82-88.
2. Rivera E, Gomez H. Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone. Breast Cancer Res 2010; 12: S2.
3. Goble S, Bear HD. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions. Surg Clin North Am 2003; 3: 43-71.
4. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92-98.
5. Salvioli S, Barbi C, Dobrucki J, Moretti L, Pinti M, Pedrazzi J, et al. Opposite role of changes in mitochondrial membrane potential in different apoptotic processes. FEBS Lett 2000; 469: 186-190.
6. Tan EH, Khoo KS, Wee J, Fong KW, Lee KS, Lee KM, et al. Phase II trial of a paclitaxel and carboplatin combination in Asian patients with metastatic nasopharyngeal carcinoma. Ann Oncol 1999; 10: 235-237.
7. O'Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer. Oncologist 2005; 3: 20-29.
8. Cortes J, Baselga J. Targeting the microtubules in breast cancer beyond taxanes: the epothilones. Oncologist 2007; 12: 271-280.
9. Iso T, Kedes L, Hamamori Y. HES and HERP families: multiple effectors of the Notch signaling pathway. J Cell Physiol 2003; 194: 237-255.
10. Bray SJ. Notch signalling: a simple pathway becomes complex. Nat Rev Mol Cell Biol 2006; 7: 678-689.
11. Nair P, Somasundaram K, Krishna S. Activated Notch1 inhibits p53-induced apoptosis and sustains transformation by human papillomavirus type 16 E6 and E7 oncogenes through a PI3KPKB/ Akt-dependent pathway. J Virol 2003; 77: 7106-7112.
12. Rangarajan A, Talora C, Okuyama R, Nicolas M, Mammucari C, Oh H, et al. Notch signaling is a direct determinant of keratinocyte growth arrest and entry into differentiation. EMBO J 2001; 20: 3427-3436.
13. Sade H, Krishna S, Sarin A. The anti-apoptotic effect of Notch-1 requires p56lck-dependent, Akt/PKB-mediated signaling in T cells. J Biol Chem 2004; 279: 2937-2944.
14. Wang Z, Banerjee S, Li Y, Rahman KM, Zhang Y, Sarkar FH. Down-regulation of notch-1 inhibits invasion by inactivation of nuclear factor-kappaB, vascular endothelial growth factor, and matrix metalloproteinase-9 in pancreatic cancer cells. Cancer Res 2006; 66: 2778-2784.
15. Real PJ, Tosello V, Palomero T, Castillo M, Hernando E, de Stanchina E, et al. Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Nat Med 2009; 15: 50-58.
16. Yu H, Zhao X, Huang S, Jian L, Qian G, Ge S. Blocking Notch1 signaling by RNA interference can induce growth inhibition in HeLa cells. Int J Gynecol Cancer 2007; 17: 511-516.
17. Li Y, Xu J, Chen L, Zhong WD, Zhang Z, Mi L, et al. HAb18G (CD147), a cancer-associated biomarker and its role in cancer detection. Histopathology 2009; 54: 677-687.
18. Abiko T, Kawamura M, Izumi Y, Oyama T, Saito Y, Kobayashi K. Prediction of anti-tumour effect of thermochemotherapy with in vitro thermochemosensitivity testing for non-small cell lung cancer. Int J Hyperthermia 2007; 23: 267-275.
19. Kawamura M, Gika M, Abiko T, Inoue Y, Oyama T, Izumi Y, et al. Clinical evaluation of chemosensitivity testing for patients with unresectable non-small cell lung cancer (NSCLC) using collagen gel droplet embedded culture drug sensitivity test (CDDST). Cancer Chemother Pharmacol 2007; 59: 507-513.
20. Kobayashi H. Collagen gel droplet culture method to examine in vitro chemosensitivity. Methods Mol Med 2005; 110: 59-67.
21. Nakahara T, Sakaeda T, Nakamura T, Tamura T, Nishioka C, Aoyama N, et al. Chemosensitivity assessed by collagen gel droplet embedded culture drug sensitivity test, and MDR1, MRP1, and MRP2 mRNA expression in human colorectal adenocarcinomas. Pharm Res 2004; 21: 406-412.
22. Blagosklonny MV, Fojo T. Molecular effects of paclitaxel: myths and reality (a critical review). Int J Cancer 1999; 83: 151-156.
23. McGrogan BT, Gilmartin B, Carney DN, McCann A. Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta 2008; 1785: 96-132.
24. Radtke F, Raj K. The role of Notch in tumorigenesis: oncogene or tumour suppressor? Nat Rev Cancer 2003; 3: 756-767.
25. Leong KG, Karsan A. Recent insights into the role of Notch signaling in tumorigenesis. Blood 2006; 107: 2223-2233.
26. Nickoloff BJ, Osborne BA, Miele L. Notch signaling as a therapeutic target in cancer: a new approach to the development of cell fate modifying agents. Oncogene 2003; 22: 6598-6608.
27. Yeh TS, Hsieh RH, Shen SC, Wang SH, Tseng MJ, Shih CM, et al. Nuclear betaII-tubulin associates with the activated notch receptor to modulate notch signaling. Cancer Res 2004; 64: 8334-8340.
28. Yeh IT, Luduena RF. The betaII isotype of tubulin is present in the cell nuclei of a variety of cancers. Cell Motil Cytoskeleton 2004; 57: 96-106.
29. Xu K, Luduena RF. Characterization of nuclear betaII-tubulin in tumor cells: a possible novel target for taxol. Cell Motil Cytoskeleton 2002; 53: 39-52.
30. Yamamoto Y, Watanabe Y, Ishida N, Hidaka T, Sugishita H, Yoshida M, et al. Collagen gel droplet-embedded culture drug sensitivity test in human breast cancer. Gan To Kagaku Ryoho 2008; 35: 793-796.